Amplify YieldShares Oil Hedged MLP Income ETF (AMLX) News
Filter AMLX News Items
AMLX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AMLX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AMLX News From Around the Web
Below are the latest news stories about AMYLYX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMLX as an investment opportunity.
Amylyx Pharmaceuticals down 3%, announces stock offeringMore on Amylyx Pharmaceuticals |
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common StockCAMBRIDGE, Mass., January 10, 2025--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per share. All of the shares are being offered by Amylyx. In addition, Amylyx has granted the underwriter a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price per share, less underwriting dis |
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockCAMBRIDGE, Mass., January 10, 2025--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Amylyx. In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the public offering at the public offering price per share, less underwriting |
Cerus And 2 Other US Penny Stocks With Promising PotentialThe U.S. stock market has recently experienced a surge, with major indexes like the Dow Jones and Nasdaq showing significant gains, driven by strong performances in technology stocks and a notable rise in Bitcoin. Amidst this backdrop, penny stocks continue to capture investor interest as they offer unique opportunities for growth at lower price points. Though often associated with smaller or newer companies, these stocks can present substantial potential when backed by solid financials and... |
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial OfficerCAMBRIDGE, Mass., January 06, 2025--Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer |
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now?We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from […] |
Amylyx announces design of LUCIDITY clinical trialAmylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist, for the treatment of post-bariatric hypoglycemia, or PBH. LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and exclusion criteria to the previous Phase 2 trials of avexitide in PBH. Amylyx expects that the first study particip |
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric HypoglycemiaCAMBRIDGE, Mass., December 04, 2024--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH). LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and exclusion criteria |
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx ConferenceCAMBRIDGE, Mass., November 27, 2024--Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference |
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)Amylyx Pharmaceuticals ( NASDAQ:AMLX ) Third Quarter 2024 Results Key Financial Results Revenue: US$416.0k (down 100... |